Trillium Therapeutics (TRIL) Gains as Cohen's Point72 Asset Shows New 5.6% Stake

Momentum stock Trillium Therapeutics (NASDAQ: TRIL) is gaining after the close (+5.9%) after Steven Cohen's family office Point72 Asset Management, L.P. (formerly SAC Capital) disclosed a 5.6%, or 378,050 share, stake in the company. The firm did not hold shares at the end of the latest quarter ending December 31, 2014.

The disclosure was made via a 13G filing, which is considered a passive investment.

You May Also Be Interested In

• Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates
• Super Micro Computer (SMCI) now down nearly 20%
• NVIDIA (NVDA) closes 10% down, wipes off over $210B in market value